Literature DB >> 16105484

Pleiotropic effects of fibrates.

Giulia Chinetti-Gbaguidi1, Jean Charles Fruchart, Bart Staels.   

Abstract

Fibrates are a widely used class of hypolipidemic drugs. The effects of fibrates are mediated through the activation of the transcription factor peroxisome proliferator-activated receptor a (PPARa). Fibrates act to modulate the transcription of genes that encode proteins controlling lipid transport and metabolism. Fibrates also exert pleiotropic anti-inflammatory effects by down regulating expression of genes encoding inflammatory cytokines and acute phase response proteins. These combined actions translate into clinical benefit as demonstrated by the reduction in cardiovascular morbidity and mortality in primary and secondary intervention trials.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16105484     DOI： 10.1007/s11883-005-0053-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  58 in total

1.  Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.

Authors:  Hélène Duez; Bruno Lefebvre; Philippe Poulain; Inés Pineda Torra; Frédéric Percevault; Gérald Luc; Jeffrey M Peters; Frank J Gonzalez; Romain Gineste; Stéphane Helleboid; Vladimir Dzavik; Jean-Charles Fruchart; Catherine Fiévet; Philippe Lefebvre; Bart Staels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-12-23       Impact factor: 8.311

2.  The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.

Authors:  Olivier Barbier; Lyne Villeneuve; Virginie Bocher; Coralie Fontaine; Ines Pineda Torra; Christian Duhem; Vladimir Kosykh; Jean-Charles Fruchart; Chantal Guillemette; Bart Staels
Journal:  J Biol Chem       Date:  2003-02-11       Impact factor: 5.157

3.  Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages.

Authors:  F G Gbaguidi; G Chinetti; D Milosavljevic; E Teissier; J Chapman; G Olivecrona; J C Fruchart; S Griglio; J Fruchart-Najib; B Staels
Journal:  FEBS Lett       Date:  2002-02-13       Impact factor: 4.124

4.  Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages.

Authors:  G Chinetti; S Lestavel; J-C Fruchart; V Clavey; B Staels
Journal:  Circ Res       Date:  2003-02-07       Impact factor: 17.367

5.  Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.

Authors:  Gérald Luc; Nelly Jacob; Muriel Bouly; Jean-Charles Fruchart; Bart Staels; Philippe Giral
Journal:  J Cardiovasc Pharmacol       Date:  2004-03       Impact factor: 3.105

6.  Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression.

Authors:  Ling Li; Marie-Claude Beauchamp; Geneviève Renier
Journal:  Atherosclerosis       Date:  2002-11       Impact factor: 5.162

Review 7.  The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.

Authors:  Jutta Dierkes; Sabine Westphal; Claus Luley
Journal:  Expert Opin Drug Saf       Date:  2004-03       Impact factor: 4.250

8.  The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha.

Authors:  Christophe Blanquart; Roxane Mansouri; Réjane Paumelle; Jean-Charles Fruchart; Bart Staels; Corine Glineur
Journal:  Mol Endocrinol       Date:  2004-05-06

9.  Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.

Authors:  Ngoc Vu-Dac; Philippe Gervois; Heidi Jakel; Maxime Nowak; Eric Bauge; Helene Dehondt; Bart Staels; Len A Pennacchio; Edward M Rubin; Jamila Fruchart-Najib; Jean-Charles Fruchart
Journal:  J Biol Chem       Date:  2003-03-12       Impact factor: 5.157

10.  Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.

Authors:  Miran Sebestjen; Irena Keber; Branka Zegura; Sasa Simcic; Mojca Bozic; Martine Migaud Fressart; Mojca Stegnar
Journal:  Thromb Haemost       Date:  2004-11       Impact factor: 5.249
View more
  7 in total

1.  The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.

Authors:  I G Sharina; M Sobolevsky; A Papakyriakou; N Rukoyatkina; G A Spyroulias; S Gambaryan; E Martin
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

Review 2.  Apolipoprotein A-I and risk for cardiovascular diseases.

Authors:  Natalie Khuseyinova; Wolfgang Koenig
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

Review 3.  Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.

Authors:  Thomas Dayspring; Gregory Pokrywka
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

4.  peroxisome proliferator-activated receptor alpha activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture.

Authors:  Momoh A Yakubu; Rami H Nsaif; Adebayo O Oyekan
Journal:  J Pharmacol Exp Ther       Date:  2006-11-14       Impact factor: 4.030

5.  Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

Authors:  Peter Willeit; Lena Tschiderer; Michael J Sweeting; Simon G Thompson; Matthias W Lorenz; Elias Allara; Kathrin Reuber; Lisa Seekircher; Lu Gao; Ximing Liao; Eva Lonn; Hertzel C Gerstein; Salim Yusuf; Frank P Brouwers; Folkert W Asselbergs; Wiek van Gilst; Sigmund A Anderssen; Diederick E Grobbee; John J P Kastelein; Frank L J Visseren; George Ntaios; Apostolos I Hatzitolios; Christos Savopoulos; Pythia T Nieuwkerk; Erik Stroes; Matthew Walters; Peter Higgins; Jesse Dawson; Paolo Gresele; Giuseppe Guglielmini; Rino Migliacci; Marat Ezhov; Maya Safarova; Tatyana Balakhonova; Eiichi Sato; Mayuko Amaha; Tsukasa Nakamura; Kostas Kapellas; Lisa M Jamieson; Michael Skilton; James A Blumenthal; Alan Hinderliter; Andrew Sherwood; Patrick J Smith; Michiel A van Agtmael; Peter Reiss; Marit G A van Vonderen; Stefan Kiechl; Gerhard Klingenschmid; Matthias Sitzer; Coen D A Stehouwer; Heiko Uthoff; Zhi-Yong Zou; Ana R Cunha; Mario F Neves; Miles D Witham; Hyun-Woong Park; Moo-Sik Lee; Jang-Ho Bae; Enrique Bernal; Kristian Wachtell; Sverre E Kjeldsen; Michael H Olsen; David Preiss; Naveed Sattar; Edith Beishuizen; Menno V Huisman; Mark A Espeland; Caroline Schmidt; Stefan Agewall; Ercan Ok; Gülay Aşçi; Eric de Groot; Muriel P C Grooteman; Peter J Blankestijn; Michiel L Bots
Journal:  Circulation       Date:  2020-06-17       Impact factor: 29.690

6.  Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function.

Authors:  Felipe Cabezas; Jonathan Lagos; Carlos Céspedes; Carlos P Vio; Miguel Bronfman; María-Paz Marzolo
Journal:  PLoS One       Date:  2011-02-02       Impact factor: 3.240

7.  Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles.

Authors:  Shanmugavel Madasamy; David Liu; Jason Lundry; Benjamin Alderete; Raymond Kong; J Paul Robinson; Alan H B Wu; Edward P Amento
Journal:  J Vis Exp       Date:  2017-11-10       Impact factor: 1.355
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.